Medical firm Suven Life Sciences informed that it has received four product patents in different international markets for its new chemical entities (NCEs) which could be used in treating various central nervous system disorders. The four product patents come from various places including Japan, Australia, Europe and Eurasia. They are valid through 2024 and 2027.
The company has received the approval for molecules which could be used in the treatment of CNS disorders like Parkinson, Alzheimer’s disease and Schizophrenia. Products out of these inventions may be out-licensed at various phases of clinical research like at phase I or phase II. With these new patents, the company now has a total of five patents from Japan, fourteen from Australia, twelve from Europe and ten from Eurasia.